Quarterly Updates26 May 2026, 07:51 pm
AstraZeneca India: FY26 Revenue at ₹22,755.8 Mn, Up 33%
AI Summary
AstraZeneca Pharma India Limited announced its FY26 results, reporting a 33% year-on-year growth in total revenue, reaching ₹22,755.8 Mn. The company saw growth in Oncology and Biopharmaceuticals, with 11 new regulatory approvals for medicines and indications. Key approvals include Durvalumab for endometrial and muscle-invasive bladder cancer, Eculizumab for rare diseases, and Osimertinib for NSCLC. The company focuses on delivering innovative medicines and addressing unmet patient needs in India.
Key Highlights
- AstraZeneca India's FY26 total revenue reached ₹22,755.8 Mn, a 33% YoY increase.
- The company received 11 regulatory approvals for medicines and indications in FY26.
- Oncology revenue stood at ₹16,100.9 Mn for FY26.
- Biopharmaceuticals revenue was ₹5,243.2 Mn for FY26.
- Eculizumab launched as first anti-complement therapy approved in India for aHUS and PNH.
Price Impact
More from ASTRAZEN